Jody A. Charnow

Editor https://www.renalandurologynews.com

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

Prostate Cancer

Study: 68Ga-PSMA-11 PET May Miss Pelvic Nodal Metastasis in Prostate Cancer

Jody A. Charnow

October 7, 2021

68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show.

Bladder Cancer

First-Line Immunotherapy, Chemotherapy for mUC of the Bladder Offer Similar Survival

Jody A. Charnow

August 30, 2021

Real-world data validate recently reported findings from clinical trials.

Treatment-Related Hospitalizations Similar for PCa Surgery, Radiation

Cardiovascular Disease (CVD)

Hyponatremia in Heart Failure Linked to High-Dose Furosemide, Spironolactone

Jody A. Charnow

August 31, 2020

In an observational study, furosemide doses of 250 to 500 mg and spironolactone doses of 50 to 100 mg were independently associated with approximately 14% and 20% increased odds of hyponatremia, respectively.

Lupus Nephritis

Low Platelet Distribution Width May Predict Lupus Nephritis

Jody A. Charnow

August 28, 2020

Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.

Focal Segmental Glomerulosclerosis (FSGS)

Kidney Function in FSGS Improves With Proteinuria Reductions

Jody A. Charnow

August 27, 2020

Each 1-unit reduction in log-transformed urinary protein-creatinine ratio in patients with focal segmental glomerulosclerosis is associated with a 77% decreased risk of end-stage kidney disease, a study found.

Upper tract urothelial carcinoma

Data Support Ureteroscopy for Upper Tract Urothelial Carcinoma

Jody A. Charnow

August 26, 2020

Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.

Bladder Cancer

Survival Remains Poor in High-Risk Muscle-Invasive Urothelial Carcinoma

Jody A. Charnow

August 18, 2020

Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.

Kidney Cancer

Metastatic RCC Subtypes Differ in Sites of Metastases

Jody A. Charnow

June 1, 2020

Lung metastases are most common in clear cell renal cell carcinoma, whereas lymph node metastases and liver metastases occur most frequently in papillary and chromophobe RCC, respectively, investigators reported.

Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to

Kidney Cancer

Tivozanib Offers Survival Benefit Similar to Sorafenib in Refractory mRCC

Jody A. Charnow

June 1, 2020

Previous findings from the TIVO-3 trial showed that tivozanib offered superior progression-free survival compared with sorafenib in patients with refractory metastatic renal cell carcinoma, but the latest analysis found no significant difference in overall survival.

Prostate Cancer

Intense Neoadjuvant ADT for High-Risk PCa Improves Pathologic Response

Jody A. Charnow

May 30, 2020

After receiving intense hormone therapy prior to radical prostatectomy, one-fifth of men with high-risk localized prostate cancer had no tumor or residual tumor smaller than 5 mm following surgery, a study found.

Next post in Prostate Cancer